Medexus Pharmaceuticals Inc (MDP.TO) surged by over 13% in the last trading session, marking a significant leap for the biotech firm.
In a remarkable display of market enthusiasm, Medexus Pharmaceuticals Inc saw its stock price soar by 13.59% in the latest trading session, closing at CA$5.10. This surge shows the company's ongoing momentum and investor confidence, especially after its recent fiscal year results.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$160.20M
52W high
$5.25
52W low
$2.47
1W change
+2.05%
Beta
1.84
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 36.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.81
+36.7% Upside
Current Price
C$4.98
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
49.8%
Annualized
90-Day Vol
42.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$5.95
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.29 | C$4.45 – C$6.28 |
| 60 trading days | C$5.61 | C$4.40 – C$7.15 |
| 90 trading days | C$5.95 | C$4.42 – C$8.02 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: With a market cap of CA$161.5 million and a focus on innovative therapies, Medexus is positioning itself as a key player in the biotech sector, making it an intriguing option for investors looking for growth opportunities.
Medexus Pharmaceuticals Inc Rises 13.59% in One Day
The stock's impressive one-day gain reflects strong investor sentiment, driven by positive fiscal performance and strategic business developments.
Bull case
The recent announcement of strong fiscal year 2026 results and the promising performance of GRAFAPEX (treosulfan) for Injection have boosted investor confidence, driving the stock's upward trend. Additionally, the company's strategic moves, like the license and supply deal for UM171 Cell Therapy, indicate a strong pipeline that could support future growth.
Bear case
Despite the positive momentum, Medexus Pharmaceuticals operates in a competitive biotech landscape where market sentiment can change quickly. The lack of dividends and a negative profit margin might concern risk-averse investors. Plus, the company's reliance on a few key products could be risky if market conditions shift.
Strong Fiscal Year Results
Advertisement
Medexus recently reported strong fiscal year 2026 results, showcasing the solid performance of its flagship product, GRAFAPEX (treosulfan) for Injection. This positive outcome has been a major factor in building investor confidence, contributing to the stock's impressive rise.
Strategic Developments
The company has also made headlines with its recent license and supply agreement for UM171 Cell Therapy in Canada. These strategic partnerships are expected to enhance Medexus's portfolio and market presence, further attracting investor interest.
Market Outlook
As Medexus Pharmaceuticals continues to navigate the competitive biotech landscape, investors will closely watch how the company leverages its recent successes. The potential for growth remains significant, but market volatility could pose challenges.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
